MedTrace Logo

Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients

NCT04358627 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2020-04-24

No results posted yet for this study

Summary

A continuous infusion of Dexmedetomidine (DEX) will be administered to 80 patients admitted to Critical Care because of signs of Respiratory Insufficiency requiring non-invasive ventilation. Measurements of respiratory performance and quantification of cellular and molecular inflammatory mediators. The primary outcome will be the avoidance of mechanical ventilation with secondary outcomes duration of mechanical ventilation, avoidance of delirium after sedation and association of mediators of inflammation to outcomes. Outcomes will be compared to a matched historical control (no DEX) series

Conditions

  • Acute Respiratory Distress Syndrome
  • Inflammation
  • Dexmedetomidine
  • Cytokine Storm
  • Delirium, Emergence

Interventions

DRUG

Dexmedetomidine Injectable Product

continuous intravenous infusion of dexmedetomidine

Sponsors & Collaborators

  • Hospital Clinic of Barcelona

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-15
Primary Completion
2020-05-30
Completion
2020-06-30
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04358627 on ClinicalTrials.gov